Abstract

A further strategy to combat the high price of anticancer drugs.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
High Drug Prices, Big R&D Spenders and 'Free Riders': Canada in the Topsy Turvy World of Pharmaceuticals
Ake Blomqvist ... Rosalie Wyonch
SSRN | VOL. -
Ake Blomqvist, et. al.Ake Blomqvist ... Rosalie Wyonch
19 Mar 2019
Therapies Out of Reach: Anticancer Drugs and Global Trade Regimes
Dwaipayan Banerjee ... James Sargent
Science Technology & Society | VOL. 23
Dwaipayan Banerjee, et. al.Dwaipayan Banerjee ... James Sargent
01 May 2018
Pharmaceutical regulation, pricing, coverage and policy reform in the United States of America
Mariana P Socal ... Fabricio Garcia
Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde | VOL. 13
Mariana P Socal, et. al.Mariana P Socal ... Fabricio Garcia
05 Sep 2022
US Pharma's Financialized Business Model
William Lazonick ... Oner Tulum
SSRN | VOL. -
William Lazonick, et. al.William Lazonick ... Oner Tulum
13 Sep 2017
View more papers

More From: Nature Reviews Clinical Oncology

Paper Title
Journal
Date
Author
Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins.
Paola Neri ... Kenneth C Anderson
Nature Reviews Clinical Oncology | VOL. -
Paola Neri, et. al.Paola Neri ... Kenneth C Anderson
03 Jul 2024
Asciminib is safe and effective in patients with newly diagnosed CML.
Diana Romero
Nature Reviews Clinical Oncology | VOL. -
Diana RomeroDiana Romero
25 Jun 2024
Vimseltinib improves outcomes in tenosynovial giant cell tumour.
David Killock
Nature Reviews Clinical Oncology | VOL. -
David KillockDavid Killock
24 Jun 2024
Promising outcomes with liso-cel in patients with R/R follicular lymphoma.
Diana Romero
Nature Reviews Clinical Oncology | VOL. -
Diana RomeroDiana Romero
21 Jun 2024
View more papers